Aegerion Pharmaceuticals (AEGR +6.5%) trades higher after Deutsche Bank reiterates Buy rating...


Aegerion Pharmaceuticals (AEGR +6.5%) trades higher after Deutsche Bank reiterates Buy rating and raises price target to $52 from $41. DB says AEGR is on track to beat guidance of 250-300 patients using Juxtapid its recently-approved treatment for a rare genetic disorder — by the end of the year.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs